Expanding the frontiers of existing antiviral drugs: possible effects of HIV-1 protease inhibitors against SARS and avian influenza.
Identifieur interne : 002738 ( PubMed/Corpus ); précédent : 002737; suivant : 002739Expanding the frontiers of existing antiviral drugs: possible effects of HIV-1 protease inhibitors against SARS and avian influenza.
Auteurs : Andrea SavarinoSource :
- Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology [ 1386-6532 ] ; 2005.
English descriptors
- KwdEn :
- Amino Acid Sequence, Animals, Antiviral Agents (therapeutic use), Birds, HIV Protease Inhibitors (therapeutic use), Humans, Influenza A virus, Influenza in Birds (drug therapy), Models, Molecular, Molecular Sequence Data, Molecular Structure, SARS Virus (drug effects), Sequence Alignment, Severe Acute Respiratory Syndrome (drug therapy).
- MESH :
- chemical , therapeutic use : Antiviral Agents, HIV Protease Inhibitors.
- drug effects : SARS Virus.
- drug therapy : Influenza in Birds, Severe Acute Respiratory Syndrome.
- Amino Acid Sequence, Animals, Birds, Humans, Influenza A virus, Models, Molecular, Molecular Sequence Data, Molecular Structure, Sequence Alignment.
Abstract
When unexpected diseases such as the severe acute respiratory syndrome (SARS) and avian influenza become a serious threat to public health, an immediate response is imperative. This should take into consideration existing licensed antiviral drugs against other viral diseases already known to be safe for use in humans. In this report, evidence is presented that HIV-1 protease inhibitors (PIs) currently used in anti-HIV-1 therapies might exert some effects on SARS and perhaps, on avian influenza. Evidence for the potential benefits of PIs against the SARS coronavirus (SARS-CoV) is provided by empirical clinical studies, in vivo viral inhibition assays and computational simulations of the docking of these compounds to the active site of the main SARS-CoV protease. As suggested by in silico docking of these molecules to a theoretical model of a subunit of type A influenza virus RNA-dependent RNA polymerase, there also exists a remote possibility that these PIs may have an effect on avian influenza viruses. Although this evidence is still far from being definitive, the results so far obtained suggest that PIs should be seriously taken into consideration for further testing as potential therapeutic agents for SARS and avian influenza.
DOI: 10.1016/j.jcv.2005.03.005
PubMed: 15893956
Links to Exploration step
pubmed:15893956Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Expanding the frontiers of existing antiviral drugs: possible effects of HIV-1 protease inhibitors against SARS and avian influenza.</title><author><name sortKey="Savarino, Andrea" sort="Savarino, Andrea" uniqKey="Savarino A" first="Andrea" last="Savarino">Andrea Savarino</name><affiliation><nlm:affiliation>Laboratory of Viral Immunology, Department of Infectious Diseases, Università Cattolica del Sacro Cuore, Largo Agostino Gemelli 8, I-00168 Rome, Italy. asavarino@medscape.com</nlm:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2005">2005</date><idno type="RBID">pubmed:15893956</idno><idno type="pmid">15893956</idno><idno type="doi">10.1016/j.jcv.2005.03.005</idno><idno type="wicri:Area/PubMed/Corpus">002738</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">002738</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Expanding the frontiers of existing antiviral drugs: possible effects of HIV-1 protease inhibitors against SARS and avian influenza.</title><author><name sortKey="Savarino, Andrea" sort="Savarino, Andrea" uniqKey="Savarino A" first="Andrea" last="Savarino">Andrea Savarino</name><affiliation><nlm:affiliation>Laboratory of Viral Immunology, Department of Infectious Diseases, Università Cattolica del Sacro Cuore, Largo Agostino Gemelli 8, I-00168 Rome, Italy. asavarino@medscape.com</nlm:affiliation></affiliation></author></analytic><series><title level="j">Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology</title><idno type="ISSN">1386-6532</idno><imprint><date when="2005" type="published">2005</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Amino Acid Sequence</term><term>Animals</term><term>Antiviral Agents (therapeutic use)</term><term>Birds</term><term>HIV Protease Inhibitors (therapeutic use)</term><term>Humans</term><term>Influenza A virus</term><term>Influenza in Birds (drug therapy)</term><term>Models, Molecular</term><term>Molecular Sequence Data</term><term>Molecular Structure</term><term>SARS Virus (drug effects)</term><term>Sequence Alignment</term><term>Severe Acute Respiratory Syndrome (drug therapy)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antiviral Agents</term><term>HIV Protease Inhibitors</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>SARS Virus</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Influenza in Birds</term><term>Severe Acute Respiratory Syndrome</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Amino Acid Sequence</term><term>Animals</term><term>Birds</term><term>Humans</term><term>Influenza A virus</term><term>Models, Molecular</term><term>Molecular Sequence Data</term><term>Molecular Structure</term><term>Sequence Alignment</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">When unexpected diseases such as the severe acute respiratory syndrome (SARS) and avian influenza become a serious threat to public health, an immediate response is imperative. This should take into consideration existing licensed antiviral drugs against other viral diseases already known to be safe for use in humans. In this report, evidence is presented that HIV-1 protease inhibitors (PIs) currently used in anti-HIV-1 therapies might exert some effects on SARS and perhaps, on avian influenza. Evidence for the potential benefits of PIs against the SARS coronavirus (SARS-CoV) is provided by empirical clinical studies, in vivo viral inhibition assays and computational simulations of the docking of these compounds to the active site of the main SARS-CoV protease. As suggested by in silico docking of these molecules to a theoretical model of a subunit of type A influenza virus RNA-dependent RNA polymerase, there also exists a remote possibility that these PIs may have an effect on avian influenza viruses. Although this evidence is still far from being definitive, the results so far obtained suggest that PIs should be seriously taken into consideration for further testing as potential therapeutic agents for SARS and avian influenza.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">15893956</PMID><DateCompleted><Year>2006</Year><Month>01</Month><Day>04</Day></DateCompleted><DateRevised><Year>2020</Year><Month>04</Month><Day>02</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1386-6532</ISSN><JournalIssue CitedMedium="Print"><Volume>34</Volume><Issue>3</Issue><PubDate><Year>2005</Year><Month>Nov</Month></PubDate></JournalIssue><Title>Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology</Title><ISOAbbreviation>J. Clin. Virol.</ISOAbbreviation></Journal><ArticleTitle>Expanding the frontiers of existing antiviral drugs: possible effects of HIV-1 protease inhibitors against SARS and avian influenza.</ArticleTitle><Pagination><MedlinePgn>170-8</MedlinePgn></Pagination><Abstract><AbstractText>When unexpected diseases such as the severe acute respiratory syndrome (SARS) and avian influenza become a serious threat to public health, an immediate response is imperative. This should take into consideration existing licensed antiviral drugs against other viral diseases already known to be safe for use in humans. In this report, evidence is presented that HIV-1 protease inhibitors (PIs) currently used in anti-HIV-1 therapies might exert some effects on SARS and perhaps, on avian influenza. Evidence for the potential benefits of PIs against the SARS coronavirus (SARS-CoV) is provided by empirical clinical studies, in vivo viral inhibition assays and computational simulations of the docking of these compounds to the active site of the main SARS-CoV protease. As suggested by in silico docking of these molecules to a theoretical model of a subunit of type A influenza virus RNA-dependent RNA polymerase, there also exists a remote possibility that these PIs may have an effect on avian influenza viruses. Although this evidence is still far from being definitive, the results so far obtained suggest that PIs should be seriously taken into consideration for further testing as potential therapeutic agents for SARS and avian influenza.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Savarino</LastName><ForeName>Andrea</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Laboratory of Viral Immunology, Department of Infectious Diseases, Università Cattolica del Sacro Cuore, Largo Agostino Gemelli 8, I-00168 Rome, Italy. asavarino@medscape.com</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>J Clin Virol</MedlineTA><NlmUniqueID>9815671</NlmUniqueID><ISSNLinking>1386-6532</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D017320">HIV Protease Inhibitors</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000595" MajorTopicYN="N">Amino Acid Sequence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001717" MajorTopicYN="N">Birds</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017320" MajorTopicYN="N">HIV Protease Inhibitors</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009980" MajorTopicYN="N">Influenza A virus</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005585" MajorTopicYN="N">Influenza in Birds</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008958" MajorTopicYN="N">Models, Molecular</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008969" MajorTopicYN="N">Molecular Sequence Data</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015394" MajorTopicYN="N">Molecular Structure</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D045473" MajorTopicYN="N">SARS Virus</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016415" MajorTopicYN="N">Sequence Alignment</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D045169" MajorTopicYN="N">Severe Acute Respiratory Syndrome</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading></MeshHeadingList><NumberOfReferences>33</NumberOfReferences></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2004</Year><Month>12</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2005</Year><Month>02</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2005</Year><Month>03</Month><Day>03</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2005</Year><Month>5</Month><Day>17</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2006</Year><Month>1</Month><Day>5</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2005</Year><Month>5</Month><Day>17</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">15893956</ArticleId><ArticleId IdType="pii">S1386-6532(05)00088-0</ArticleId><ArticleId IdType="doi">10.1016/j.jcv.2005.03.005</ArticleId><ArticleId IdType="pmc">PMC7108403</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Hong Kong Med J. 2003 Dec;9(6):399-406</Citation><ArticleIdList><ArticleId IdType="pubmed">14660806</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Clin Virol. 2001 Feb;20(3):131-5</Citation><ArticleIdList><ArticleId IdType="pubmed">11166661</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Infect Dis. 2005 Apr 15;191(8):1381-2; author reply 1382-3</Citation><ArticleIdList><ArticleId IdType="pubmed">15776390</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Bioorg Med Chem. 2004 May 15;12(10):2517-21</Citation><ArticleIdList><ArticleId IdType="pubmed">15110833</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Biol Chem. 2004 Jan 16;279(3):1637-42</Citation><ArticleIdList><ArticleId IdType="pubmed">14561748</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>EMBO Rep. 2001 Apr;2(4):313-7</Citation><ArticleIdList><ArticleId IdType="pubmed">11306552</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Arch Virol. 2003 Sep;148(9):1687-96</Citation><ArticleIdList><ArticleId IdType="pubmed">14505082</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Science. 2003 Jun 13;300(5626):1763-7</Citation><ArticleIdList><ArticleId IdType="pubmed">12746549</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Proc Natl Acad Sci U S A. 2003 Nov 11;100(23):13190-5</Citation><ArticleIdList><ArticleId IdType="pubmed">14585926</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Acquir Immune Defic Syndr. 2004 Mar 1;35(3):223-32</Citation><ArticleIdList><ArticleId IdType="pubmed">15076236</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Infect Dis. 1999 Aug;180(2):448-53</Citation><ArticleIdList><ArticleId IdType="pubmed">10395861</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Biochem Biophys Res Commun. 2004 Oct 8;323(1):264-8</Citation><ArticleIdList><ArticleId IdType="pubmed">15351731</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Protein Expr Purif. 2003 Dec;32(2):302-8</Citation><ArticleIdList><ArticleId IdType="pubmed">14965777</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>BMC Struct Biol. 2003 Apr 1;3:2</Citation><ArticleIdList><ArticleId IdType="pubmed">12675950</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Clin Infect Dis. 2004 Apr 1;38(7):1030-2</Citation><ArticleIdList><ArticleId IdType="pubmed">15034838</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Infect. 2004 Nov;49(4):262-73</Citation><ArticleIdList><ArticleId IdType="pubmed">15474623</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Thorax. 2004 Mar;59(3):252-6</Citation><ArticleIdList><ArticleId IdType="pubmed">14985565</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Biochem Biophys Res Commun. 2004 Nov 12;324(2):579-83</Citation><ArticleIdList><ArticleId IdType="pubmed">15474466</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Acquir Immune Defic Syndr. 2003 Oct 1;34(2):242-3</Citation><ArticleIdList><ArticleId IdType="pubmed">14526215</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Biol Chem. 2004 Jun 4;279(23):24765-73</Citation><ArticleIdList><ArticleId IdType="pubmed">15037623</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Biol Chem. 1999 Dec 10;274(50):35734-40</Citation><ArticleIdList><ArticleId IdType="pubmed">10585454</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Genes Cells. 2001 Feb;6(2):87-97</Citation><ArticleIdList><ArticleId IdType="pubmed">11260254</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Virol. 2002 Sep;76(18):8989-9001</Citation><ArticleIdList><ArticleId IdType="pubmed">12186883</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>AIDS. 2002 Mar 29;16(5):693-700</Citation><ArticleIdList><ArticleId IdType="pubmed">11964525</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Bioorg Med Chem Lett. 2003 Nov 17;13(22):3989-92</Citation><ArticleIdList><ArticleId IdType="pubmed">14592491</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Lancet Infect Dis. 2003 Nov;3(11):722-7</Citation><ArticleIdList><ArticleId IdType="pubmed">14592603</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Infect Dis. 2004 Apr 1;189(7):1164-7</Citation><ArticleIdList><ArticleId IdType="pubmed">15031783</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Proc Natl Acad Sci U S A. 2001 Jun 5;98(12):6895-900</Citation><ArticleIdList><ArticleId IdType="pubmed">11371613</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Biochem Biophys Res Commun. 2004 Jun 4;318(3):719-25</Citation><ArticleIdList><ArticleId IdType="pubmed">15144898</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Clin Virol. 2004 Sep;31(1):69-75</Citation><ArticleIdList><ArticleId IdType="pubmed">15288617</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/SrasV1/Data/PubMed/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002738 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd -nk 002738 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= SrasV1
|flux= PubMed
|étape= Corpus
|type= RBID
|clé= pubmed:15893956
|texte= Expanding the frontiers of existing antiviral drugs: possible effects of HIV-1 protease inhibitors against SARS and avian influenza.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/RBID.i -Sk "pubmed:15893956" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a SrasV1
| This area was generated with Dilib version V0.6.33. |  |